137 related articles for article (PubMed ID: 23547647)
21. Association between community pharmacy loyalty and persistence and implementation of antipsychotic treatment among individuals with schizophrenia.
Zongo FE; Moisan J; Grégoire JP; Lesage A; Dossa AR; Lauzier S
Res Social Adm Pharm; 2018 Jan; 14(1):53-61. PubMed ID: 28077240
[TBL] [Abstract][Full Text] [Related]
22. Is drug insurance status an effect modifier in epidemiologic database studies? The case of maternal asthma and major congenital malformations.
Blais L; Kettani FZ; Forget A; Beauchesne MF; Lemière C
Birth Defects Res A Clin Mol Teratol; 2015 Dec; 103(12):995-1002. PubMed ID: 25846426
[TBL] [Abstract][Full Text] [Related]
23. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
Kennedy J; Morgan S
Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
[TBL] [Abstract][Full Text] [Related]
24. Persistence with treatment in newly treated middle-aged patients with essential hypertension.
Perreault S; Lamarre D; Blais L; Dragomir A; Berbiche D; Lalonde L; Laurier C; St-Maurice F; Collin J
Ann Pharmacother; 2005 Sep; 39(9):1401-8. PubMed ID: 16076920
[TBL] [Abstract][Full Text] [Related]
25. Use and reimbursement costs of smoking cessation medication under the Quebec public drug insurance plan.
Tremblay M; Payette Y; Montreuil A
Can J Public Health; 2009; 100(6):417-20. PubMed ID: 20209733
[TBL] [Abstract][Full Text] [Related]
26. Antidepressant Prescription Claims Among Reproductive-Aged Women With Private Employer-Sponsored Insurance - United States 2008-2013.
Dawson AL; Ailes EC; Gilboa SM; Simeone RM; Lind JN; Farr SL; Broussard CS; Reefhuis J; Carrino G; Biermann J; Honein MA
MMWR Morb Mortal Wkly Rep; 2016 Jan; 65(3):41-6. PubMed ID: 26821271
[TBL] [Abstract][Full Text] [Related]
27. Economic impact of nonpersistence with antidepressant treatment in the adult population of Quebec: a comparative cost-effectiveness approach.
Béland SG; Tournier M; Galbaud du Fort G; Crott R; Ducruet T; Pariente A; Moride Y
Value Health; 2011 Jun; 14(4):492-8. PubMed ID: 21669374
[TBL] [Abstract][Full Text] [Related]
28. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Wang J; Liu X; Mullins CD
Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
[TBL] [Abstract][Full Text] [Related]
29. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
30. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
31. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting.
Yaldo AZ; Wertz DA; Rupnow MF; Quimbo RM
Clin Ther; 2008 Dec; 30(12):2452-60. PubMed ID: 19167603
[TBL] [Abstract][Full Text] [Related]
32. Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants.
Wang PS; Patrick AR; Dormuth C; Maclure M; Avorn J; Canning CF; Schneeweiss S
J Ment Health Policy Econ; 2010 Mar; 13(1):37-44. PubMed ID: 20571181
[TBL] [Abstract][Full Text] [Related]
33. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
Sedjo RL; Cox ER
Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
[TBL] [Abstract][Full Text] [Related]
34. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
Jiang Y; Ni W
Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
[TBL] [Abstract][Full Text] [Related]
35. Clearance of psoriasis: the impact of private versus public insurance.
Buzney CD; Peterman C; Saraiya A; Au SC; Dumont N; Mansfield R; Gottlieb AB
J Drugs Dermatol; 2015 Feb; 14(2):119-25. PubMed ID: 25689806
[TBL] [Abstract][Full Text] [Related]
36. Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance.
Blais L; Couture J; Rahme E; LeLorier J
Health Policy; 2003 May; 64(2):163-72. PubMed ID: 12694953
[TBL] [Abstract][Full Text] [Related]
37. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance.
Hertz RP; Unger AN; Lustik MB
Clin Ther; 2005 Jul; 27(7):1064-73. PubMed ID: 16154485
[TBL] [Abstract][Full Text] [Related]
38. Accuracy of the days' supply and the number of refills allowed recorded in Québec prescription claims databases for inhaled corticosteroids.
Blais L; Vilain A; Kettani FZ; Forget A; Lalonde G; Beauchesne MF; Ducharme FM; Lemière C
BMJ Open; 2014 Nov; 4(11):e005903. PubMed ID: 25432902
[TBL] [Abstract][Full Text] [Related]
39. Persistence of antidepressant treatment for depressive disorder in Taiwan.
Wu CS; Shau WY; Chan HY; Lai MS
Gen Hosp Psychiatry; 2013; 35(3):279-85. PubMed ID: 23415578
[TBL] [Abstract][Full Text] [Related]
40. Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective.
Lachaine J; Beauchemin C; Sasane R; Hodgkins PS
Postgrad Med; 2012 May; 124(3):139-48. PubMed ID: 22691908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
